Varicella Zoster Infection in Renal Transplant Recipients: Prevalence, Complications and Outcome

被引:31
|
作者
Mustapic, Z. [1 ]
Basic-Jukic, N. [1 ]
Kes, P. [1 ]
Lovcic, V. [1 ]
Bubic-Filipi, Lj. [1 ]
Mokos, I. [2 ,3 ]
Kastelan, Z. [2 ,3 ]
Zekan, S. [4 ]
机构
[1] Clin Hosp Ctr Zagreb, Dept Nephrol Arterial Hypertens & Dialysis, HR-10000 Zagreb, Croatia
[2] Clin Hosp Ctr Zagreb, Dept Urol, HR-10000 Zagreb, Croatia
[3] Univ Zagreb, Sch Med, Zagreb 41001, Croatia
[4] Clin Hosp Infect Dis Fran Mihaljevic, Zagreb, Croatia
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2011年 / 34卷 / 06期
关键词
Renal transplantation; Immunosuppression; Varicella zoster; Mycophenolate mofetil; Varicella zoster virus infection; SOLID-ORGAN TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; ALLOGRAFT RECIPIENTS; ACUTE REJECTION; KIDNEY-TRANSPLANTATION; HERPES-ZOSTER; RISK-FACTORS; HEPATITIS-B; VIRUS; DISEASE;
D O I
10.1159/000328730
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Varicella zoster virus (VZV) is an important pathogen after renal transplantation. In the present study, we examined the prevalence, clinical presentation and outcome of VZV infections in renal transplant recipients. Charts and medical records of adult renal allotransplant recipients were investigated to find patients with VZV infection. From December 1972 until July 2010, 1,139 patients received kidney allograft at our institution. VZV infection was diagnosed in 40 patients (3.51%). 28 patients (70%) had intensified immunosuppression prior to VZV infection occurrence. Median time of onset was 2.13 years after transplantation (range 9 days to 19.2 years). 35 patients developed VZV during the first post-transplant year (median 0.61 years). Four patients developed VZV infection more than 12 years after transplantation. 33 patients (82.5%) had dermatomal distribution, 5 (12.5%) disseminated herpes zoster (HZ), and 2 patients (5%) who were VZV IgG-negative before transplantation, developed chickenpox. Immunosuppression was reduced and patients received acyclovir. Cutaneous scarring was recorded in 7 cases (17.5%). Two patients developed post-herpetic neuralgia, which was accompanied by scarring and skin depigmentation in 1 of them. Five patients (12.5%) experienced relapse of HZ. Timely initiation of therapy may prevent development of complications and the visceral form of disease. Based on our experience with development of chickenpox, we suggest active immunization for all seronegative patients before organ transplantation. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:382 / 386
页数:5
相关论文
共 50 条
  • [31] Urological complications in renal transplant recipients
    不详
    JOURNAL OF ENDOUROLOGY, 2005, 19 : A50 - A50
  • [32] Infectious complications in renal transplant recipients
    Tanphaichitr, NT
    Brennan, DC
    ADVANCES IN RENAL REPLACEMENT THERAPY, 2000, 7 (02): : 131 - 146
  • [33] Gastrointestinal complications in renal transplant recipients
    Ponticelli, C
    Passerini, P
    TRANSPLANT INTERNATIONAL, 2005, 18 (06) : 643 - 650
  • [34] Neurological complications of varicella-zoster virus infection in children
    Fraszczak, Justyna
    Mania, Anna
    Kemnitz, Pawel
    Mazur-Melewska, Katarzyna
    Figlerowicz, Magdalena
    AKTUALNOSCI NEUROLOGICZNE, 2021, 21 (04): : 231 - 237
  • [35] Infectious complications in renal transplant recipients
    Splendiani, G
    Cipriani, S
    Tisone, G
    Iorio, B
    Condo, S
    Vega, A
    Dominijanni, S
    Casciani, CU
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) : 2497 - 2499
  • [36] Infectious complications in renal transplant recipients
    Parasuraman, Ravi
    Yee, Jerry
    Karthikeyan, Vanji
    del Busto, Ramon
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2006, 13 (03) : 280 - 294
  • [39] Cardiac complications in children following infection with varicella zoster virus
    Abrams, D
    Derrick, G
    Penny, DJ
    Shinebourne, EA
    Redington, AN
    CARDIOLOGY IN THE YOUNG, 2001, 11 (06) : 647 - 652
  • [40] The treatment of varicella-zoster virus infection and its complications
    Partridge, David G.
    McKendrick, Michael W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (05) : 797 - 812